Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

2-Year Event-Free and Overall Survival in PTCL

J Clin Oncol; ePub 2017 Oct 26; Maurer, et al

Although patients with peripheral T-cell lymphoma (PTCL) with primary refractory disease or early relapse experience extremely poor survival, those who remain in remission 2 years after they are diagnosed tend to survive longer, researchers concluded after conducting a study involving 775 individuals. Participants were treated for newly diagnosed PTCL between 2000 and 2012 at a median 64 years of age. Investigators looked at event-free and overall survival. Among the results:

  • 64% of patients experienced disease progression within the first 24 months and had a median overall survival of ~5 months (5-year survival rate of 11%).
  • Median overall survival after achieving event-free survival at 24 months was not reached (5-year survival rate of 78%).
  • Nearly one-fourth of patients who achieved event-free survival at 24 months relapsed within 5 years.
  • Overall survival rate in patients ≤60 years of age who achieved event-free survival at 24 months was 91%.

Citation:

Maurer M, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral t-cell lymphoma. [Published online ahead of print October 26, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.73.8195.

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Aggressive Lymphomas

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505

ADC + BR improves response rate in diffuse large B-cell lymphoma, Sehn LH et al. EHA Congress, Abstract S802.